This brand name is authorized in Austria, Australia, Brazil, Canada, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom
The drug SKYRIZI contains one active pharmaceutical ingredient (API):
|
1
Risankizumab
UNII 90ZX3Q3FR7 - RISANKIZUMAB
|
|
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine and inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines. Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| SKYRIZI Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L04AC18 | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 11827L, 11858D |
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 543719110004107 |
| Country: CA | Health Products and Food Branch | Identifier(s): 02487454 |
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 174-MBE-0121, 235-MBE-0822 |
| Country: EE | Ravimiamet | Identifier(s): 1794102, 1848416, 1848427, 1848438 |
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 1191361001 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 055240, 409325, 557887 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 67060271 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 371219, 397916, 397922 |
| Country: HK | Department of Health Drug Office | Identifier(s): 66488 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 9258, 9259, 9314, 9315 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 3999450A1025, 3999450G1028, 3999450G2024, 3999450G3020, 3999450G4027 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1087673, 1092291, 1092292 |
| Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 197629 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 20126, 21860, 21949 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100417814, 100461473 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W66053001, W67699001, W67700001, W69348001, W69349001 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8680656080520, 8680656080599, 8680656080605 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
